Anti-CD19 CAR-T cell therapy has been demonstrated to induce high rates of durable remissions in adult patients with lymphoma and chronic lymphocytic leukemia as well as in children with acute lymphoblastic leukemia (ALL) (117–126). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.